https://orcid.org/0000-0002-5594-9075
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: This study aimed to investigate the role of LINC00513 in colorectal cancer (CRC) progression. Materials & methods: Cell proliferation was evaluated using Cell Counting Kit-8. Cell migration was detected with transwell assay. RNA pull-down was applied for verifying the interactions between LINC00513, IGF2BP1 and connective tissue growth factor (CTGF). Results: LINC00513, IGF2BP1 and CTGF levels were upregulated in CRC. Knockdown of LINC00513 significantly inhibited the malignant behavior of CRC cells. LINC00513 increased CTGF mRNA stability by binding with IGF2BP1. Furthermore, overexpression of IGF2BP1 or CTGF reversed the inhibitory effect of LINC00513 shRNA on CRC progression. Conclusion: LINC00513 promoted CRC cell malignant behaviors through IGF2BP1/CTGF.
Plain language summary
Colorectal cancer (CRC) progression seriously threatens the health of people. This study showed that LINC00513 (a long noncoding RNA), insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1) and connective tissue growth factor (CTGF) were significantly upregulated in CRC tissues. Furthermore, the knockdown of LINC00513 inhibited CRC malignant progression in vitro. Mechanistically, LINC00513 increased CTGF mRNA stability in CRC cells by binding with IGF2BP1. As expect, the impact of LINC00513 downregulation on CRC cell proliferation and migration was declined by the overexpression of IGF2BP1 or CTGF. Taken together, LINC00513 upregulation promoted CRC malignant progression by regulating the IGF2BP1/CTGF axis. We believe that this study will help overcome CRC.
GRAPHICAL ABSTRACT
The dysregulation of LINC00513, IGF2BP1 & CTGF in CRC
LINC00513 was upregulated in colorectal cancer (CRC).
IGF2BP1 and connective tissue growth factor (CTGF) were increased in CRC.
The role of LINC00513 in regulating CRC malignant development
LINC00513 could promote the malignant behavior of CRC cells.
The interactions between LINC00513, IGF2BP1 & CTGF
LINC00513 could interact with IGF2BP1.
IGF2BP1 could bind with CTGF.
LINC00513 upregulation increased CTGF mRNA stability by binding with IGF2BP1 in CRC cells.
The roles of IGF2BP1/CTGF in LINC00513-induced oncogenic effects on CRC
Overexpression of IGF2BP1 reversed the promotion of LINC00513 on CRC malignant progression.
Overexpression of CTGF inhibited the oncogenic effect of LINC00513 on CRC malignant progression.
Author contributions
W Lun, X Zhang and Y Hong designed this study. W Lun, C Luo and Y Liu collected the materials and performed the experiments. W Lun, X Zhang and Y Hong analysed the data and wrote the manuscript. W Lun revised the manuscript. All authors read and approved the final version of the manuscript.
Financial disclosure
This study was supported by the Health Commission of Guangdong Province (B2021311). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
This manuscript has been edited for English language, grammar, punctuation and spelling by Enago, the editing brand of Crimson and funded by the Health Commission of Guangdong Province (B2021311).
Ethical conduct of research
The ethics committee of Foshan Nanhai District People’s Hospital of Guangdong Province (The Sixth Affiliated Hospital, School of Medicine, South China University of Technology) agreed with the present study (the approval number of the ethics committee: 2023006). All participants provided informed consent with their signed names.